The EU’s pharmaceutical overhaul would classify medicines used to treat infectious diseases as vaccines, then exclude those vaccines from the gene therapy category. That is the wording in the Council’s text.
‼️Dringender Appell an alle EU-Parlamentarier‼️
Das EU-Parlament stimmt am 25. November 2026 darüber ab, ob wir EU-Bürger in Zukunft definitiv autoritären Maßnahmen mit experimentellen gentechnischen Substanzen ausgesetzt werden können und damit für lange Zeit unserer… pic.twitter.com/szqecb7Xav— RA/Avv. DDr. Renate Holzeisen (@RHolzeisen) November 19, 2026
New EU pharma rules are coming, to power health sector innovation, improve medicine access and secure supply chains. 💊
Join the discussion on how to put the new rules into action on 7 December.
Follow live: https://t.co/OiTnLlefOq pic.twitter.com/XzBIjh2CV6
— EU One Health (@EU_Health) November 19, 2026
The distinction has consequences. Gene therapy products made with synthetic or recombinant nucleic acids fall under specific safety rules. Infectious-disease vaccines are carved out of that definition, meaning those gene-therapy-specific requirements do not automatically apply. And the vaccine definition now expressly covers treatment, not just prevention.
This doesn’t mean the products face no testing. It means they can fall under a different set of rules. With Parliament due to vote November 25, the question is why this broader exemption is being written into EU law and how many products could qualify.
https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=consil:ST_12263_2026_INIT
https://oeil.europarl.europa.eu/oeil/cs/procedure-file?reference=2023%2F0132%28COD%29
If you got something out of this, please chip in to keep this site running, or subscribe to go ad-free.
1 view